TU München, Klinikum recht der Isar
Welcome,         Profile    Billing    Logout  
 1 Trial 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Witteler, Ralf
MAMOC, NCT04227522: Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

Completed
3
42
Europe
Rucaparib, Placebos
North Eastern German Society of Gynaecological Oncology, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Clovis Oncology, Inc.
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Clear Cell Carcinoma
12/23
07/24
MIROVA, NCT04274426 / 2018-004207-39: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Active, not recruiting
2
136
Europe
Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine
AGO Research GmbH, ImmunoGen, Inc.
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
12/25
12/26
NCT06433219: Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Recruiting
2
60
Europe, US, RoW
Tuvusertib (M1774), M1774, VXc-400, VRT-1363004, substance code MSC2584415A, Niraparib, GSK3985771, MK-4827, Lartesertib (M4076), M4076, substance code MSC2585823A
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Ovarian Cancer
01/28
01/28
SENTICOL III, NCT03386734: International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer

Active, not recruiting
N/A
989
Europe, Canada, Japan, RoW
SLN biopsy only, SLN biopsy + PLN dissection
Centre Hospitalier Universitaire de Besancon, ARCAGY/ GINECO GROUP, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Cervical Cancer
05/27
05/29
Bronger, Holger
MIROVA, NCT04274426 / 2018-004207-39: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Active, not recruiting
2
136
Europe
Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine
AGO Research GmbH, ImmunoGen, Inc.
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
12/25
12/26
WoO, NCT04644289 / 2020-005101-12: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

Recruiting
2
60
Europe
olaparib, Lynparza, durvalumab, Imfinzi
AGO Research GmbH, AstraZeneca GmbH
Epithelial Ovarian Cancer
01/28
06/28
ECLAT, NCT03438474: Endometrial Cancer Lymphadenectomy Trial

Recruiting
N/A
640
Europe, Japan, RoW
Standard surgical procedure for endometrial cancer, systematic lymphadenectomy (LNE)
Philipps University Marburg, German Cancer Aid
Cancer of Endometrium Stage I, Cancer of Endometrium Stage II
02/28
02/29

Download Options